Allegheny Financial Group LTD Lineage Cell Therapeutics, Inc. Transaction History
Allegheny Financial Group LTD
- $424 Million
- Q2 2025
A detailed history of Allegheny Financial Group LTD transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Allegheny Financial Group LTD holds 20,000 shares of LCTX stock, worth $37,600. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,000
Previous 20,000
-0.0%
Holding current value
$37,600
Previous $9,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding LCTX
# of Institutions
137Shares Held
99.6MCall Options Held
368KPut Options Held
0-
Broadwood Capital Inc New York, NY49.6MShares$93.2 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.48MShares$15.9 Million0.0% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.1 Million6.02% of portfolio
-
Comerica Bank4.6MShares$8.65 Million0.02% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $319M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...